Skip to main content

Enjaymo Disease Interactions

There are 4 disease interactions with Enjaymo (sutimlimab).

Moderate

Sutimlimab (applies to Enjaymo) autoimmune disease

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Autoimmune Disorder

Sutimlimab may increase the risk for developing autoimmune diseases such as systemic lupus erythematosus (SLE). Patients with SLE or autoimmune disease with positive antinuclear antibody were excluded from clinical trials with sutimlimab. In clinical trials, some patients developed a relapse or worsening of autoimmune disease. Patients receiving sutimlimab should be monitored for signs/symptoms and managed medically.

References

  1. (2023) "Product Information. Enjaymo (sutimlimab)." Bioverativ Therapeutics Inc, SUPPL-3
Moderate

Sutimlimab (applies to Enjaymo) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

The effects of liver dysfunction on the pharmacokinetics of sutimlimab are unknown.

References

  1. (2023) "Product Information. Enjaymo (sutimlimab)." Bioverativ Therapeutics Inc, SUPPL-3
Moderate

Sutimlimab (applies to Enjaymo) infections

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Sutimlimab may increase susceptibility to serious infections, including those caused by encapsulated bacteria. If this drug is administered to patients with active systemic infections, close monitoring for signs/symptoms of worsening infection is recommended. Interruption of treatment should be considered in patients who are undergoing treatment for serious infection. Patients should be vaccinated and/or revaccinated against encapsulated bacteria according to clinical recommendations, ideally at least 2 weeks before starting treatment. Sutimlimab has not been studied in chronic infections such a hepatitis B, hepatitis C, or HIV.

References

  1. (2023) "Product Information. Enjaymo (sutimlimab)." Bioverativ Therapeutics Inc, SUPPL-3
Moderate

Sutimlimab (applies to Enjaymo) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

The effects of severe renal dysfunction on the pharmacokinetics of sutimlimab are unknown.

References

  1. (2023) "Product Information. Enjaymo (sutimlimab)." Bioverativ Therapeutics Inc, SUPPL-3

Enjaymo drug interactions

There are 58 drug interactions with Enjaymo (sutimlimab).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer